Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 26:17:1877-1885.
doi: 10.2147/IJWH.S521303. eCollection 2025.

Lymphadenectomy and Sentinel Lymph Node Biopsy in Patients with Endometrial Cancer in Intermediate and High-Intermediate Risk Groups: The Ukrainian Experience

Olha Khoptiana  1 , Valentyn Svintsitskyi  1 , Sergiy Nespryadko  1 , Natalia P Tsip  1 , Teimuraz Gogisvanidze  2 , Mikheil Dzimistarishvili  2 , Dmytro Krasylenko  2 , Mykhailo Serhiiovych Chetverikov  3 , Igor Pavlovych Nigutsa  3   4 , Dmytro Sumtsov  4 , Pavlo Dolyk  5
Affiliations

Lymphadenectomy and Sentinel Lymph Node Biopsy in Patients with Endometrial Cancer in Intermediate and High-Intermediate Risk Groups: The Ukrainian Experience

Olha Khoptiana et al. Int J Womens Health. .

Abstract

Purpose: To analyze the oncological safety of sentinel lymph node biopsy compared to lymphadenectomy. Additionally, we evaluated the postoperative complications of the two methods.

Patients and methods: This retrospective multicenter trial included 118 patients with intermediate and high-intermediate Stage I-II endometrioid endometrial cancer. Patients with non-endometrioid tumors and those with lymphadenopathy detected on computed tomography were excluded. The study group underwent sentinel lymph node biopsy. In contrast, the control group underwent systematic lymphadenectomy up to the renal vessels, the level of the inferior mesenteric artery, or the bifurcation of the iliac vessels. Recurrence-free survival was calculated using the Kaplan-Meier method. Differences were considered statistically significant at p < 0.05 (95% confidence interval).

Results: Patients were recruited from 2017 to March 2024. In the control group, six (5.9%) patients experienced disease recurrence and five (4.2%) died. Overall, two (1.7%) patients from both groups died from causes unrelated to recurrence. Recurrence-free survival did not significantly differ between those who underwent sentinel lymph node biopsy (96.3%, SE ± 0.036) and those who underwent lymphadenectomy (89.4%, SE ± 0.045) over 3 years from the date of surgery to the time of the first recurrence (p = 0.608). Eighteen postoperative complications were identified: 11 (9.3%) patients experienced complications within 30 days of follow-up, and 7 (5.9%) within 90 days.

Conclusion: Sentinel lymph node biopsy may serve as an alternative to systemic lymphadenectomy for surgical staging without compromising recurrence-free survival.

Keywords: endometrial cancer; lymphadenectomy; sentinel lymph node biopsy.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Patient flowchart.
Figure 2
Figure 2
Kaplan–Meier curve for recurrence-free survival in patients from the two groups: 1 – sentinel lymph node biopsy, 2 – systematic lymphadenectomy.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Panici PB, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707–1716. doi: 10.1093/jnci/djn397 - DOI - PubMed
    1. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125–136. doi: 10.1016/S0140-6736(08)61766-3 - DOI - PMC - PubMed
    1. Daraï E, Dubernard G, Bats AS, et al. Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study. Gynecol Oncol. 2015;136(1):54–59. doi: 10.1016/j.ygyno.2014.09.011 - DOI - PubMed
    1. Persson J, Salehi S, Bollino M, Lönnerfors C, Falconer H, Geppert B. Pelvic sentinel lymph node detection in high-risk endometrial cancer (SHREC-trial)—the final step towards a paradigm shift in surgical staging. Eur J Cancer. 2019;116:77–85. doi: 10.1016/j.ejca.2019.04.025 - DOI - PubMed
    1. Capozzi VA, Rosati A, Maglietta G, et al. Long-term survival outcomes in high-risk endometrial cancer patients undergoing sentinel lymph node biopsy alone versus lymphadenectomy. Int J Gynecol Cancer. 2023;33(7):1013–1020. doi: 10.1136/ijgc-2023-004314 - DOI - PubMed

LinkOut - more resources